Study of Compound Edaravone Injection for Treatment of Acute Ischemic Stroke

Active, not recruiting

Phase 3 Results N/A

Summary of Purpose

The primary objective of the study is to confirm the efficacy of compound Edaravone Injection via intravenous infusion every 12 hours in the patients with Acute Ischemic Stroke(AIS) in a double-blind, active-controlled manner. The study is also to examine the safety of compound Edaravone Injection for the AIS patients.

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 19 April 2016.

1 May 2015 20 Apr 2015 1 Oct 2016 1 Dec 2016 1 Apr 2016 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Design

  • Allocation: Randomized
  • Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
  • Purpose: Treatment
  • Endpoint: Safety/Efficacy Study
  • Intervention: Parallel Assignment